Insider Selling: Liquidia (NASDAQ:LQDA) Director Sells $7,574,000.00 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 100,000 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $75.74, for a total value of $7,574,000.00. Following the sale, the director owned 880,073 shares in the company, valued at approximately $66,656,729.02. This represents a 10.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Liquidia Price Performance

Shares of NASDAQ LQDA opened at $78.17 on Friday. The stock has a market cap of $6.95 billion, a PE ratio of 558.40 and a beta of 0.58. Liquidia Corporation has a fifty-two week low of $11.85 and a fifty-two week high of $79.41. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. The stock has a fifty day moving average of $56.77 and a 200-day moving average of $43.74.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. The company had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.Liquidia’s revenue was up 4187.1% on a year-over-year basis. Equities research analysts anticipate that Liquidia Corporation will post 2.97 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Wells Fargo & Company increased their price target on shares of Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Raymond James Financial restated a “strong-buy” rating and issued a $68.00 price objective on shares of Liquidia in a research report on Thursday, June 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. HC Wainwright increased their target price on shares of Liquidia from $67.00 to $75.00 and gave the stock a “buy” rating in a research note on Friday, June 5th. Finally, Needham & Company LLC raised their price target on shares of Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a report on Monday, May 11th. Three equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Liquidia has a consensus rating of “Moderate Buy” and a consensus price target of $67.43.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Liquidia in the 4th quarter worth approximately $25,000. NewEdge Advisors LLC bought a new position in shares of Liquidia during the 2nd quarter valued at $25,000. FNY Investment Advisers LLC purchased a new position in Liquidia in the 3rd quarter worth $34,000. Covestor Ltd raised its position in Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after purchasing an additional 359 shares during the period. Finally, Tower Research Capital LLC TRC lifted its stake in Liquidia by 281.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock worth $83,000 after purchasing an additional 4,927 shares during the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).